|
10 Jan 2021 |
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
|
|
10 Jan 2021 |
Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
|
|
10 Jan 2021 |
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
|
|
10 Jan 2021 |
U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
|
|
07 Jan 2021 |
UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis
|
|
06 Jan 2021 |
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
|
|
06 Jan 2021 |
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
|
|
06 Jan 2021 |
Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic and Advance Two Additional Irreversible Preclinical Programs
|
|
06 Jan 2021 |
Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient
|
|
06 Jan 2021 |
Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
|
|
06 Jan 2021 |
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
|
|
06 Jan 2021 |
Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds
|
|
06 Jan 2021 |
Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease
|
|
05 Jan 2021 |
Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis
|
|
05 Jan 2021 |
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
|
|
05 Jan 2021 |
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
|
|
05 Jan 2021 |
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
|
|
05 Jan 2021 |
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
|
|
04 Jan 2021 |
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
|
|
04 Jan 2021 |
Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis
|
|
02 Jan 2021 |
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
|
|
02 Jan 2021 |
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
|
|
31 Dec 2020 |
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
|
|
29 Dec 2020 |
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder
|
|
29 Dec 2020 |
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
|
